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Deposition of the β-amyloid (Aβ) peptide is thought to underlie development of Alzheimer's disease (AD).This
pathological linkage has spurred considerable interest in therapeutic strategies to reduce Aβ production. It
is becoming increasingly clear that altered cholesterol homeostasis can modulate Aβ production and/or
accumulation. In this review, we discuss the molecular pathology of AD, the cholesterol connection and recent
data suggesting that the oxysterol receptor, liver X receptor LXR (NR1H2 and NR1H3), may modulate these
events.
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Epidemiology of Alzheimer′s disease
Alzheimer’s disease (AD) is characterized by a
progressive, age-related cognitive decline that ultimately
results in memory loss, loss of language skills, difficulty
performing routine tasks, disorientation and personality
changes. Approximately 4.5 million people in the US
currently suffer from AD and the incidence has been
estimated at ~20% for individuals >75 years of age
[Hebert et al., 2003].The outlook is bleak in our aging
population: disease prevalence doubles every 5 years
over age of 65 and the number of affected individuals is
expected to reach 13 million by 2050 [Hebert et al., 2003].
This estimate is a conservative one, since metabolic
disease may increase the risk of AD, and
hypercholesterolemia, diabetes and obesity are at
epidemic levels. Anti-cholinesterases are currently used
to limit the progression of AD but their effectiveness is
far from ideal.There is thus a critical need to understand
the molecular events that underlie AD and to translate
this information into more effective therapies.
Molecular pathology of AD
The two pathological hallmarks of AD are the
accumulation of intracellular neurofibrillary tangles and
extracellular amyloid plaques (also known as senile or
neuritic plaques).The major constituent of the amyloid
plaque is a peptide known as Aβ or β-amyloid [Masters
et al., 1985;Wong et al., 1985] and aggregation of this
peptide is now accepted as a causative factor in the
disease [Hardy and Selkoe, 2002].The Aβ peptide arises
via cleavage of the amyloid precursor protein (APP), a
glycosylated, single transmembrane protein that is a
substrate for several membrane bound proteases (Figure
1). APP is first cleaved by either α- or β-secretase.This
cleavage occurs in the extra-cellular or lumenal space
[Kinoshita et al., 2003;Kojro et al., 2001] to yield a
105-125 kDa secreted N-terminal fragment (APPα or
APPβ), and the membrane-bound C-terminal fragment
(CTF).The CTF is subsequently cleaved in the
golgi-endosomal network by γ-secretase [Pasternak et
al., 2003;Siman and Velji, 2003].This protease cleaves
the CTF within the intra-membrane domain between
37-43 amino acids C-terminal to the β-secretase site.The
γ-secretase products are referred to as Aβ (β-CTF) or p3
(α-CTF) as they are derived from cleavage by β/γ- or
α/γ-secretases, respectively.The most common
β/γ-secretase cleaved product is Aβ40 (85-95%), with
Aβ42 (5-15%) being the second most abundant product.
Note that the initial “choice” between α- and β-secretase
has dramatic consequences for AD: cleavage by
β/γ-secretase results in Aβ production whereas
α-secretase cleaves within the Aβ sequence.Thus,
α-secretase not only precludes formation of Aβ but results
in production of the non-amyloidogenic p3 peptide. It
should be noted that the sequence of the mouse Aβ
peptide diverges slightly from that of humans and has
less predilection to aggregate into plaques. As a result,
murine models of AD were developed by transgenic
expression of human APP with familial mutations.
Cholesterol and Alzheimer’s
The role of cholesterol in the pathogenesis of AD came
to the forefront in 2000, when two groups independently
reported that subjects that were treated with
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase
inhibitors – the statins – had a significantly lower
prevalence of AD. In both studies, the statins decreased
AD outcome by about 70% [Jick et al., 2000;Wolozin et
al., 2000].The statins act by inhibiting synthesis of
mevalonic acid, a rate-limiting metabolite produced early
in the cholesterol biosynthetic pathway.These findings
suggest that elevated levels of cholesterol or some other
biologically active precursor (e.g. farnesylpyrophosphate,
geranylgeranylpyrophosphate) is associated with the
development of AD. In support of a specific connection
to cholesterol, four studies have reported an association
between mild hypercholesterolemia and risk for AD. In
earlier work, Sparks et al. [Sparks et al., 1993] had found
that subjects who died of atherosclerotic heart disease,
which is associated with elevated total cholesterol, had
significantly greater numbers of amyloid plaques
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The cholesterol-statin-AD link has also been observed in
experimental settings. Fassbender et al. [Fassbender et
al., 2001] showed that guinea pigs fed large doses of
simvastatin for as little as three weeks had 50% lower
brain Aβ levels compared to the controls. In addition,
high-cholesterol diets resulted in elevated intraneuronal
Aβ levels in rabbits (Aβ sequence identical to humans),
and increased plaque formation in transgenic mice
expressing human APP [Refolo et al., 2000;Sparks, 1996].
Figure 1.  Proteolytic processing of Aβ-Precursor Protein (APP)
by α-, β-, and γ-secretase. (A) The single-transmembrane
domain-containing full-length APP is shown along with the cleavage sites
for α-, β-, and γ-secretase. (B) Non-amyloidogenic processing of APP.
α-secretase cleaves APP in the extracellular space to yield the N-terminal
secreted APPα fragment and the transmembrane domain-containing
α-CTF.The α-CTF is then cleaved by the γ-secretase to produce the
non-amyloidogenic p3 and γ-CTF fragments. (C) Amyloidogenic processing
of APP. APP is cleaved by β-secretase in the extracellular domain to
produce APPβ and β-CTF.The γ-secretase can cleave β-CTF at position
40 or 42 amino-acids C-terminal to the β-secretase site.Thus, the
β/γ-secretase cleavage yields the amyloidogenic Aβ40 (orange) and Aβ42
peptides (orange + red), and γ-CTF.
If AD arises via an increase in Aβ
production/accumulation, how do alterations in cholesterol
homeostasis affect the development of this disease? The
answer may lie in the fact that APP/Aβ processing occurs
within cholesterol-rich membrane domains, i.e. APP and
the β- and γ-secretases are localized in cholesterol-rich
lipid rafts [Bouillot et al., 1996;Ehehalt et al., 2003;Marlow
et al., 2003;Riddell et al., 2001;Wahrle et al., 2002].
Cholesterol homeostasis in the brain
Much like the liver, the brain expresses the machinery
required for cholesterol uptake, intracellular trafficking,
de novo synthesis and metabolic degradation. In the
periphery, apolipoprotein AI (apoAI) and apolipoprotein
E (apoE) serve as the major extracellular cholesterol
acceptors. ApoE is a ligand for all members of the LDL
receptor family, and directly mediates hepatic uptake of
very low-density lipoprotein (VLDL). In the brain,
extracellular cholesterol is transported via lipoprotein-like
particles that contain astroglia- and microglia-derived
apoE and apoJ [Danik et al., 1999].The apoE-containing
particles are endocytosed by neuronal lipoprotein receptor
related protein (LRP) [Williams et al., 1998]. As in the
periphery, these lipoprotein complexes are
tran0073ported to lysosomes through endosomal
pathways and ultimately other compartments via the
Neiman-Pick C1 protein (NPC1) [Runz et al., 2002;Zhang
et al., 2001].
It is important to note that lipoproteins cannot pass the
blood-brain barrier.This has two critical implications. First,
peripheral and central cholesterol pools are not readily
interchangeable and are largely maintained as separate
pools [Koch et al., 2001]. Second, the brain cannot rely
on peripherally-derived cholesterol to satisfy its massive
cholesterol requirements. Instead, the brain produces its
own cholesterol via the standard HMG-CoA
reductase-limited biosynthetic pathway. As in the liver,
excess cholesterol is removed via catabolism to more
polar degradation products: the liver utilizes CYP7A1
(cholesterol 7α-hydroxylase) to metabolize cholesterol
to bile acids whereas the brain predominantly utilizes
CYP46 (cholesterol 24-hydroxylase) to convert cholesterol
to 24(S)-hydroxycholesterol [Lund et al., 2003].This
24-hydroxylated metabolite can exit via the blood-brain
barrier where it is further metabolized and ultimately
eliminated by the liver.
APP/Aβ processing and cholesterol
trafficking
Although total cholesterol levels are tightly regulated in
the brain, the precise location of individual cholesterol
molecules can be highly dynamic due to endosomal
uptake pathways and NPC1-mediated intracellular
trafficking. Moreover, the concentration of cholesterol in
different intracellular membranes is not uniform:
cholesterol content increases successively from the
endoplasmic reticulum to the plasma membrane, and
within the plasma membrane, cholesterol is organized
into distinct structural pools that include lipid rafts and
caveolae. Presence of cholesterol within the membrane
alters the fluidity of the surrounding membranes and
impacts biological events that occur within those
membranes [Schroeder et al., 2001].Thus, dysregulation
of cholesterol trafficking could contribute to AD as
β/γ-secretase dependent APP/Aβ processing occurs within
cholesterol-rich lipid rafts and endosomes.
Several lines of evidence support the above hypothesis.
Intracellular cholesterol trafficking can be altered by
expressing an NPC1 mutant.This leads to the
accumulation of cholesterol in late endosomes and
lysosomes. Mice expressing the mutated NPC1 show no
changes in amounts of α- or β-secretase activity but
exhibit increased γ-secretase activity and accumulate
Aβ40 and Aβ42. Increased activity occurs without any
detectable change in the amount of the PS1 subunit of
γ-secretase.This suggests that changes in membrane
www.nursa.org  NRS  | 2004 |  Vol. 2 |  DOI: 10.1621/nrs.02001 | Page 2 of 6
Review Lipids, Alzheimer's and LXRscholesterol distribution stimulates γ-secretase activity and
ultimately Aβ production [Burns et al., 2003]. Similarly,
treatment of neurons with drugs that block cholesterol
trafficking from lysosomes (U18666A, imipramine) also
increased γ-secretase activity [Runz et al., 2002].
Enhanced γ-secretase activity was associated with
abnormal localization of γ-secretase subunits (PS1 and
PS2) in cholesterol sorting vesicular compartments.Thus,
changes in membrane cholesterol trafficking appear to
alter the activity of γ-secretase, a membrane bound APP
processing enzyme.
Treatment of cells with statins and cholesterol-depleting
agents suggest that cholesterol may also affect the other
APP processing enzymes, i.e. α- and β-secretase.
Specifically, decreasing cholesterol is associated with a
rise in the non-amyloidogenic activity of α-secretase and
a decrease in the amyloidogenic β-secretase activity
[Fassbender et al., 2001;Kojro et al., 2001;].The net effect
of these changes are consistent with the AD-promoting
effects of cholesterol.The differential effects on α- and
β-secretase may be related to the fact that α-secretase
is primarily active at the cell-surface, while β-secretase
(BACE) is associated with lipid rafts [Kojro et al.,
2001;Riddell et al., 2001].This distinct localization of the
α- and β-secretase also suggests that α-cleavage of APP
could be accentuated if APP is retained longer on the cell
surface. In agreement, Kojro et al. [Kojro et al., 2001]
found that depletion of membrane cholesterol increased
membrane fluidity, decreased endocytosis, and was
associated with increased α-cleavage and less Aβ.
Other interventions that alter cellular cholesterol transport
have also been shown to alter APP cleavage. For
example, overexpression of the ABCA1 lipid transporter
reduced Aβ secretion in Neuro2a cells (murine
neuroblastoma) expressing human APP with a swedish
familial mutation (APPswe, Figure 1) [Sun et al., 2003].
Although ABCA1 can promote cholesterol efflux from
macrophages, little cholesterol efflux was observed in
these Neuro2a cells. It has been suggested that ABCA1
is primarily a phospholipid transporter; its ability to
promote cholesterol efflux may be secondary to an
ABCA1-mediated redistribution of cholesterol from inner
to outer membrane surfaces [Vaughan and Oram, 2003]
followed by the binding of the outer membrane cholesterol
to extracellular acceptor proteins (e.g. apoAI and apoE).
In adipocytes, ABCA1 has been shown to shift cholesterol
from membranes to lipid droplets [Le Lay et al., 2003].
Thus, the ABCA1-dependent reduction of Aβ may be
related with cholesterol redistribution rather than efflux.
When viewed as a whole, this body of literature suggests
that intracellular cholesterol depletion and/or redistribution
has important consequences for the proteolytic processing
of APP and the production of Aβ.
LXR and cholesterol homeostasis
There are a number of interesting links between the Liver
X Receptors (LXRα/NR1H3 and LXRβ/NR1H2) and the
above biology. LXRα was originally identified as an
orphan receptor highly expressed in hepatic tissue.
Subsequent studies demonstrated that LXRs are central
players in cholesterol homeostasis throughout the
periphery (for detailed reviews see [Joseph and Tontonoz,
2003;Joseph and Tontonoz, 2003]. Briefly, LXRα is
abundant in tissues that metabolize cholesterol including
liver, intestine and macrophages ; LXRβ is ubiquitously
expressed. Both receptors bind to and are activated by
cholesterol derived oxysterol ligands.When activated by
ligand, LXRs induce CYP7A-1 mediated cholesterol
degradation in the liver (rodents) and promote cholesterol
efflux from macrophages, hepatocytes and intestinal
enterocytes. Enhanced efflux is mediated by
LXR-dependent activation of cholesterol/lipid transporters
(ABCA1, ABCG1, ABCG5 and ABCG8) and cholesterol
acceptor proteins (apoE).These effects are biologically
significant as synthetic LXR agonists increase plasma
HDL cholesterol, stimulate cholesterol excretion into the
bile and the feces, decrease hepatic cholesterol content
and can reduce atherosclerotic lesions by ~50% in various
murine models [Cao et al., 2002;Joseph et al.,
2002;Plosch et al., 2002;Schultz et al., 2000;Yu et al.,
2003].
So what about LXRs and the brain? Both subtypes are
expressed in the CNS at significant levels: LXRα mRNA
levels range from 7-29% of that in the liver, while LXRβ
levels are 2-5 fold higher in the brain than in liver.The
levels of LXRα in cultured neurons and glia are 2% and
17% compared to the liver, and that for LXRβ are 1.1-
and 3.8-fold, respectively [Whitney et al., 2002]. Are these
receptors functional? The answer is yes. Astrocytes
treated with synthetic LXR ligands exhibit enhanced
cholesterol efflux and increased expression of LXR target
genes including ABCA1, ABCG1, and apoE [Fukumoto
et al., 2002;Koldamova et al., 2003;Liang et al.,
2004;Whitney et al., 2002]. Lxrα/β-null mice show a
variety of CNS defects including lipid accumulation,
astrocyte proliferation and disorganized myelin sheaths
[Joseph et al., 2002].These studies demonstrate that
LXRs modulate cholesterol homeostasis in the CNS and
are required for normal CNS function.
Is there a connection between LXRs and
AD?
The discussion above suggests that modulators of
intracellular cholesterol content and/or distribution can
modulate APP processing. LXR clearly meets this criterion
and offers other potentially intriguing links to AD. For
example, polymorphisms in apoE, an LXR-regulated
gene, is the strongest predictor of late-onset AD [Corder
et al., 1993]. CYP46 (cholesterol-24-hydroxylase)
polymorphisms have also been linked to AD [Kolsch et
al., 2002; Papassotiropoulos et al., 2003] and expression
of this enzyme is shifted from neurons to glia in AD
patients [Bogdanovic et al., 2001]. CYP46 converts
cholesterol into an oxysterol ligand
(24(S)-hydroxycholesterol) that can bind and activate
LXRs in cultured cells. Although it remains unclear
whether 24(S)-hydroxycholesterol is the active ligand that
is bound to LXRs in vivo, these intriguing coincidences
provide additional impetus to explore an LXR – AD
connection.
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Three recent publications demonstrate that LXRs can
indeed modulate proteolytic-processing of APP, albeit
with conflicting conclusions.The Rebeck lab [Fukumoto
et al., 2002] demonstrated that LXR agonists
(22(R)-hydroxycholesterol or T0901317) increased both
ABCA1 expression and Aβ secretion in Neuro2A cells;
exogenous cholesterol carrier was not added.The
increase in Aβ was likely mediated via ABCA1 as siRNA
targeting this transporter decreased Aβ production. Using
two human neuroblastoma cell-lines stably expressing
APPswe, the Lazo lab [Koldamova et al., 2003] also
observed the expected increase in ABCA1 expression,
enhanced cholesterol efflux and subsequent decrease in
total cellular cholesterol. However, in sharp contrast to
the previous group, LXR agonist
(22(R)-hydroxycholesterol) reduced Aβ production. In
these experiments, addition of apoA1 or apoE to the
culture medium promoted significant cholesterol efflux,
which was associated with further reduction in Aβ.Tall’s
group also found that LXR agonist (T0901317) enhanced
ABCA1 expression and decreased Aβ production in
mouse Neuro2A cells expressing human APPswe [Sun
et al., 2003].The reduction in Aβ was related to a
decrease in β- and γ-secretase cleavage. Moreover, the
decrease in Aβ could be mimicked by overexpression of
wild-type ABCA1 but not by a mutant that was defective
in cholesterol transport and apoAI binding. However,
ABCA1-mediated reduction in Aβ was observed under
conditions where there was little or no cholesterol or
phospholipid efflux (i.e. without apoAI or apoE in the
media).Thus unlike Rebeck’s group, both Lazo and Tall’s
groups find that LXR inhibits Aβ by inducing ABCA1
activity. Some discussion remains as to whether the
relevant activity of ABCA1 is intracellular cholesterol
redistribution vs. lipid efflux.The reasons for the
discrepancies among the 3 groups could be related to
differences in cell lines (mouse vs. human; wild-type vs.
APPswe+) and/or other methodologies.
Where do we go from here?
The potential to treat AD with a nuclear receptor ligand
is quite exciting. However, given the above discrepancies,
it will be critical to determine the net effect of LXR
agonists on APP processing in vivo. Experiments in cell
culture will be valuable in sorting through mechanistic
questions but given the interactions between neurons
and glia, it will be important to look at LXR effects in an
in vivo setting.This is complicated by the choice of animal
model. As mentioned above, the wild-type mouse does
not develop AD pathology as the mouse Aβ peptide does
not aggregate.This particular problem has been
overcome by expressing human APP variants in several
transgenic mouse models.This is not a perfect solution
for many reasons, not the least of which is that cholesterol
homeostasis is differentially regulated in mouse and man.
Indeed, this issue has come to the forefront before for
LXR. LXR agonists can raise HDL-cholesterol in several
mouse models. However, mice do not express cholesteryl
ester transfer protein (CETP) and the effects of LXR
agonists on HDL-cholesterol are lost in transgenic mice
expressing human CETP [Masson et al., 2004].When it
comes to cholesterol homeostasis and AD, these tales
remind us to exercise more than the usual caution when
extrapolating results to humans.
Another area of future interest is the relationship between
peripheral and central cholesterol homeostasis and how
LXR may contribute to each. As described above, it is
believed that peripheral and central cholesterol pools are
largely distinct. If this is the case, how does excess dietary
cholesterol promote Aβ accumulation [Refolo et al.,
2000]? Similarly, some of the statins that lower AD-risk
are considered relatively impermeable to the blood-brain
barrier [Wolozin et al., 2000].These findings raise the
possibility of important interactions between peripheral
and central cholesterol homeostasis and that peripheral
targets may be viable for anti-AD therapy.The effect of
peripheral vs. central effects is particularly relevant to
LXR as it can directly regulate cholesterol homeostasis
in both compartments.
Summary
Cholesterol is proving to be an important factor in the
development of AD. Population studies suggest that mild
hypercholesterolemia can increase the risk of AD and
decreasing cholesterol synthesis via statin administration
may decrease the development of AD. Moreover, elevated
cellular cholesterol content has been shown to favor
production of the amyloid-β (Aβ) peptide, a pathognomic
hallmark of AD. Genetic studies have suggested links
between AD and several cholesterol control genes
including the cholesterol acceptor ApoE (ε4
polymorphism). LXR is expressed in the brain where it
modulates cholesterol homeostasis and possibly APP
processing. Many questions remain, but as a master
regulator of cholesterol homeostasis, LXR can be
considered a potential molecular target for the treatment
of AD.
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